CNXU

The company's core technology is a collagen extracellular matrix scaffold platform. This platform is designed to support the body's own tissue repair processes, aiming to regenerate tissue with minimal inflammation or scar formation. Its products are being developed for a range of applications, including facial rejuvenation, body contouring for areas like the breasts and buttocks, and wound care. These collagen-based scaffolds are positioned as potential alternatives to traditional dermal fillers or surgical implants.

Conexeu's lead investigational product is a collagen gel, known as CXU collagen gel, which is intended for both therapeutic and aesthetic uses. The company's offerings are currently in the investigational stage, supported by preclinical data, and are pending regulatory clearances for commercial use. It targets professionals in the medical aesthetics, regenerative medicine, and clinical wound care sectors, serving clinicians who perform these procedures. Founded in 2022, the company is advancing its pipeline through the necessary development and regulatory pathways.